Medication info
Nexpo Tablet 10/160 mg

Nexpo Tablet 10/160 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tablet
Manufacturer / importer
Youngil Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202001097 · Approved 2020.02.18 · Insurance code 649405260

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (amlodipine or valsartan); however, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to this medicine may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher); however, this medicine should not be administered to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients 65 years of age and older: Use caution when increasing the dose.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Youngil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or valsartan monotherapy.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (amlodipine or valsartan); however, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to this medicine may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher); however, this medicine should not be administered to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients 65 years of age and older: Use caution when increasing the dose.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimester of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals who are allergic to this medication or similar classes of drugs, those who are pregnant or breastfeeding, and those with severe kidney or liver disease should not take this medication. Caution is advised when administering this medication to patients who are depleted of sodium or fluids, as hypotension may occur; blood pressure should be carefully monitored before and after administration. Patients with high potassium levels or those taking medications that can increase potassium levels should have their potassium levels checked frequently. Patients with vascular problems in the kidneys or those who have undergone kidney transplants may experience a risk of worsening kidney function while taking this medication. If symptoms of angioedema, such as swelling of the face, lips, or tongue, occur during treatment with this medication, it should be discontinued immediately, and a physician should be consulted. Patients with heart failure or those recovering from myocardial infarction should closely monitor kidney function while on this medication, and it should be used cautiously in patients with severe heart failure. This medication can interact with other antihypertensives, diuretics, and potassium-sparing agents, so any other medications being taken should be reported to a physician or pharmacist. Caution is needed as dizziness or fatigue may occur when driving or operating machinery. In case of overdose, severe hypotension or cardiac arrhythmias may occur, and immediate medical attention should be sought. This medication is not recommended for individuals under age 18, as its safety and efficacy have not been sufficiently established.

Side effects

nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, positional dizziness, paresthesia, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, itching, joint swelling, low back pain, arthritis, muscle spasms, lethargy, polyuria, nocturia, erectile dysfunction, edema, localized edema, facial edema, peripheral edema, fatigue, flushing, weakness, facial flushing, hemoglobin decrease, hematocrit decrease, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, angioedema, myalgia, renal failure, kidney damage, increased serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infection, intestinal vascular edema, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremor, sensory impairment, dysgeusia, peripheral neuropathy, muscular hypertonicity, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urinary disturbance, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, increased liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, neural hyperexcitability, Stevens-Johnson syndrome, arthralgia, skeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it should be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness for a longer period.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.